Form 4: Xeris Biopharma Executive Reports Changes in Beneficial Ownership

Kenneth Erland Johnson, a Senior Vice President at Xeris Biopharma Holdings, reported changes in his beneficial ownership of company stock due to tax withholding on vested RSUs and participation in the employee stock purchase plan.

Summary

• Kenneth Erland Johnson, a Senior Vice President at Xeris Biopharma Holdings, filed a Form 4 detailing changes in his beneficial ownership of Xeris Biopharma Holdings, Inc. [XERS] stock.
• The reported transactions primarily involve the withholding of shares by the issuer to satisfy income tax obligations related to the net settlement of Restricted Stock Units (RSUs) that vested on various dates.
• These dates include January 29, 2022, January 31, 2022, January 3, 2023, January 29, 2023, January 31, 2023, January 3, 2024, January 29, 2024 and January 31, 2024.
• Additionally, the report indicates the purchase of 1,080 shares on June 30, 2024, through participation in the company's 2018 Employee Stock Purchase Plan.
• Following these transactions, Johnson directly owns 373,036 shares of Xeris Biopharma Holdings common stock.

Sentiment

Score: 5

Explanation: The document primarily reports routine transactions related to stock vesting and tax obligations. The late filing is a minor negative, but overall the document doesn't convey strong positive or negative sentiment.

Positives

• The reporting individual's participation in the Employee Stock Purchase Plan indicates confidence in the company's future.

Negatives

• The Form 4 filing was reported late due to administrative oversight.

Risks

• Administrative oversights in reporting requirements could lead to regulatory scrutiny.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The transactions reported have a minimal direct impact on stakeholders.

Key Dates